{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001869","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.374484+00:00","generated_at":"2026-06-17T19:56:20.367022+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aptose reports Q4 net loss $10.0M; cash runway into Q1 2024; tuspetinib expansion trial underway","bullets":["Q4 net loss $10.0M ($0.11/sh) vs $24.3M loss year ago; FY2022 net loss $41.8M ($0.45/sh) vs $65.4M.","Cash and investments $47.0M at Dec 31, 2022; expects funding into Q1 2024.","APTIVATE Phase 1/2 expansion trial for tuspetinib initiated; monotherapy and TUS/VEN combination arm enrolling.","Tuspetinib monotherapy showed 29% CR/CRh in RAS-mutated AML patients during dose escalation.","Luxeptinib G3 formulation shows improved bioavailability; continuous dosing ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001869","json":"https://secwatch.observer/filing/0001171843-23-001869.json","markdown":"https://secwatch.observer/filing/0001171843-23-001869.md","text":"https://secwatch.observer/filing/0001171843-23-001869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/0001171843-23-001869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/f8k_032323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T19:56:20.367022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bf3c338f1df970dcbbf192024560c800429a01f","claim":"Aptose Biosciences Inc. reported the quarter ended December 31, 2022 results: net income $10.0 million, EPS ($0.11 per share).","evidence_excerpt":"The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/0001171843-23-001869-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Net income","value":"$10.0 million"},{"label":"EPS","value":"($0.11 per share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"57f474dde59f56d4cdcba2cd83bd156058a6aa9c","claim":"Aptose Biosciences Inc. reported the year ended December 31, 2022 results: net income $41.8 million, EPS ($0.45 per share).","evidence_excerpt":"The net loss for the year ended December 31, 2022, was $41.8 million ($0.45 per share) compared with $65.4 million ($0.73 per share) for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/0001171843-23-001869-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$41.8 million"},{"label":"EPS","value":"($0.45 per share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}